These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 15954652)

  • 1. In situ delivery of therapeutic cytokines by genetically engineered Lactococcus lactis.
    Steidler L
    Meded Rijksuniv Gent Fak Landbouwkd Toegep Biol Wet; 2001; 66(3b):551, 553-6. PubMed ID: 15954652
    [No Abstract]   [Full Text] [Related]  

  • 2. In situ delivery of cytokines by genetically engineered Lactococcus lactis.
    Steidler L
    Antonie Van Leeuwenhoek; 2002 Aug; 82(1-4):323-31. PubMed ID: 12369199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of ovalbumin-specific tolerance by oral administration of Lactococcus lactis secreting ovalbumin.
    Huibregtse IL; Snoeck V; de Creus A; Braat H; De Jong EC; Van Deventer SJ; Rottiers P
    Gastroenterology; 2007 Aug; 133(2):517-28. PubMed ID: 17681173
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heterologous protein production and delivery systems for Lactococcus lactis.
    Nouaille S; Ribeiro LA; Miyoshi A; Pontes D; Le Loir Y; Oliveira SC; Langella P; Azevedo V
    Genet Mol Res; 2003 Mar; 2(1):102-11. PubMed ID: 12917806
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic drug delivery by genetically modified Lactococcus lactis.
    Steidler L; Rottiers P
    Ann N Y Acad Sci; 2006 Aug; 1072():176-86. PubMed ID: 17057198
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Relief effect of beta-galactosidase genetically engineered lactococcus lactis on the cell toxicity caused by lactose].
    Liu X; Lü XY; Yu Q; Zhang CW
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2006 Jan; 37(1):52-4. PubMed ID: 16468641
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Engineered and wild-type L. lactis promote anti-inflammatory cytokine signalling in inflammatory bowel disease patient's mucosa.
    Simčič S; Berlec A; Stopinšek S; Štrukelj B; Orel R
    World J Microbiol Biotechnol; 2019 Feb; 35(3):45. PubMed ID: 30810891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biological containment of genetically modified Lactococcus lactis for intestinal delivery of human interleukin 10.
    Steidler L; Neirynck S; Huyghebaert N; Snoeck V; Vermeire A; Goddeeris B; Cox E; Remon JP; Remaut E
    Nat Biotechnol; 2003 Jul; 21(7):785-9. PubMed ID: 12808464
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral administration of an IL-10-secreting Lactococcus lactis strain prevents food-induced IgE sensitization.
    Frossard CP; Steidler L; Eigenmann PA
    J Allergy Clin Immunol; 2007 Apr; 119(4):952-9. PubMed ID: 17316776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention and treatment of colitis with Lactococcus lactis secreting the immunomodulatory Yersinia LcrV protein.
    Foligne B; Dessein R; Marceau M; Poiret S; Chamaillard M; Pot B; Simonet M; Daniel C
    Gastroenterology; 2007 Sep; 133(3):862-74. PubMed ID: 17678918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Progress on lactococcus lactis expressing heterologous antigens as live mucosal vaccines].
    Shi D; Song Y; Li YJ
    Wei Sheng Wu Xue Bao; 2006 Aug; 46(4):680-3. PubMed ID: 17037080
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunology. Therapeutic manipulation of gut flora.
    Shanahan F
    Science; 2000 Aug; 289(5483):1311-2. PubMed ID: 10979858
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting diseases with genetically engineered Lactococcus lactis and its course towards medical translation.
    Villatoro-Hernandez J; Montes-de-Oca-Luna R; Kuipers OP
    Expert Opin Biol Ther; 2011 Mar; 11(3):261-7. PubMed ID: 21204744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetically engineered Lactococcus lactis secreting murine IL-10 modulates the functions of bone marrow-derived dendritic cells in the presence of LPS.
    Loos M; Remaut E; Rottiers P; De Creus A
    Scand J Immunol; 2009 Feb; 69(2):130-9. PubMed ID: 19144079
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Production of biologically active CXC chemokines by Lactococcus lactis: evaluation of its potential as a novel mucosal vaccine adjuvant.
    Cortes-Perez NG; da Costa Medina LF; Lefèvre F; Langella P; Bermúdez-Humarán LG
    Vaccine; 2008 Oct; 26(46):5778-83. PubMed ID: 18790708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paracellular entry of interleukin-10 producing Lactococcus lactis in inflamed intestinal mucosa in mice.
    Waeytens A; Ferdinande L; Neirynck S; Rottiers P; De Vos M; Steidler L; Cuvelier CA
    Inflamm Bowel Dis; 2008 Apr; 14(4):471-9. PubMed ID: 18092343
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of bioactive porcine interferon-gamma by recombinant Lactococcus lactis.
    Rupa P; Monedero V; Wilkie BN
    Vet Microbiol; 2008 May; 129(1-2):197-202. PubMed ID: 18164876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of the route of immunization and the nature of the bacterial vector on immunogenicity of mucosal vaccines based on lactic acid bacteria.
    Cortes-Perez NG; Lefèvre F; Corthier G; Adel-Patient K; Langella P; Bermúdez-Humarán LG
    Vaccine; 2007 Sep; 25(36):6581-8. PubMed ID: 17675182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Production of biological active murine IFN-gamma by recombinant Lactococcus lactis.
    Bermúdez-Humarán LG; Cortes-Perez NG; L'Haridon R; Langella P
    FEMS Microbiol Lett; 2008 Mar; 280(2):144-9. PubMed ID: 18248432
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dynamics of genetically modified Lactococcus lactis in simulated natural environments and impacts on microbial communities.
    Hagi T; Minagawa A; Shima J
    J Biosci Bioeng; 2009 Mar; 107(3):339-43. PubMed ID: 19269603
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.